Status:
RECRUITING
Dupixent and Narrowband UVB for Atopic Dermatitis
Lead Sponsor:
Psoriasis Treatment Center of Central New Jersey
Collaborating Sponsors:
Regeneron Pharmaceuticals
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
Detailed Description
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
Eligibility Criteria
Inclusion
- Male or female adult ≥ 18 years of age;
- Diagnosis of moderate to severe atopic dermatitis as defined at baseline by:
- EASI score of 16 or greater,
- IGA score of 3 or greater
- BSA of 10% or greater,
Exclusion
- Subjects with previous exposure to dupilumab.
- Known or suspected hypersensitivity to dupilumab or any of its excipients.
- History of photosensitivity.
Key Trial Info
Start Date :
April 19 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 15 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05285839
Start Date
April 19 2022
End Date
December 15 2024
Last Update
March 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Eczema Treatment Center of New Jersey
East Windsor, New Jersey, United States, 08520